Alabama is currently home to 1233 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
LOWER: Lomitapide Observational Worldwide Evaluation Registry
NCT02135705
Recruiting
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Gender:
ALL
Ages:
All
Trial Updated:
03/11/2024
Locations: Brookwood Baptist Medical Center, Birmingham, Alabama
Conditions: Homozygous Familial Hypercholesterolemia
Register for Updates
Community Stroke Self-management Program
NCT06251128
Recruiting
This pilot project aims develop a need-based community stroke self-management program that would improve the stroke self-management self-efficacy and competencies among African American stroke survivors living in rural Alabama. This study is a mixed-methods study to collect data related to the needs of these individuals and develop a need-based intervention based on the actual needs/ preferences of our target population. The specific aims are to assess the needs, access barriers, existing resour... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/08/2024
Locations: The Hale County extension Office, Greensboro, Alabama
Conditions: Stroke, Blood Pressure
Register for Updates
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
NCT01574053
Recruiting
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: University of Alabama, Birmingham, Alabama
Conditions: Huntington's Disease
Register for Updates
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
NCT04169321
Recruiting
First in Human Safety of \[68Ga\]-NOTA-hGZP PET Imaging in subjects with cancer undergoing treatment with a checkpoint inhibitor either as a monotherapy of in combination I-O therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Solid Tumor, Unspecified, Adult, Lymphoma
Register for Updates
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)
NCT05600777
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/14/2024
Locations: G & L Research, LLC, Gulf Shores, Alabama
Conditions: Refractory Chronic Cough
Register for Updates
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05599191
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/14/2024
Locations: Jasper Summit Research, LLC, Jasper, Alabama
Conditions: Refractory Chronic Cough
Register for Updates
The Influence of Aerobic Exercise on Consolidation of Fear Extinction Learning in PTSD
NCT06144203
Recruiting
This study aims to test whether aerobic exercise performed after fear extinction learning improves cognitive, physiological, and neural indices of extinction recall in a sample of trauma-exposed men and women with and without posttraumatic stress disorder (PTSD). Participants will complete a clinical intake visit (Day 0), followed by a three-day fear conditioning (day 1), fear extinction + activity (day 2), and fear extinction recall (day 3) protocol.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
02/13/2024
Locations: Wade Hall - University of Alabama, Tuscaloosa, Alabama
Conditions: PTSD
Register for Updates
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT04673617
Recruiting
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituxim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: University of Alabama, Birmingham, Alabama
Conditions: Non Hodgkin Lymphoma
Register for Updates
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
NCT04137900
Recruiting
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Register for Updates
Mitochondria Oxidative Stress and Vascular Health Study
NCT05561556
Recruiting
Cardiovascular diseases (CVDs) are the number one cause of death in America and most of the post-industrial world. Hypertension is a leading risk factor for CVDs including stroke, myocardial infarction, and heart failure. Black Americans suffer from the highest rates of hypertension of any racial/ethnic group in America, among the highest in the world. There are also well-documented racial disparities in vascular dysfunction (e.g., endothelial dysfunction, arterial stiffening). Thus, racial disp... Read More
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
01/29/2024
Locations: Auburn University, Auburn, Alabama
Conditions: Cardiovascular Diseases, Hypertension, Racism, Vascular Diseases
Register for Updates
Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
NCT06218199
Recruiting
The DART-HA study is a single-center, open label, trial intended to evaluate the clinical efficacy of standard treatment options for congestive heart failure (observation, diuretic or afterload reduction therapy) in patients without new symptoms who have developed abnormalities of the HeartLogic heart failure diagnostic feature.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
01/25/2024
Locations: Heart Center Research, LLC, Huntsville, Alabama
Conditions: Heart Failure, Congestive
Register for Updates
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
NCT05338697
Recruiting
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: University of Alabama, Birmingham, Alabama
Conditions: Stroke, Stroke, Acute, Stroke, Ischemic, Stroke Hemorrhagic
Register for Updates